Uncategorized
RXi initiates phase 1/2 clinical trial of RXI-109 for retinal scarring
RXi Pharmaceuticals has initiated RXI-109-1501, a phase 1/2 clinical trial evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, according to a press release. RXI-109-1501 includes patients diagnosed with wet age-related macular degeneration who will receive a total of four doses of RXI-109 in one eye only at 1-month intervals. The dosing period will last 3 months and will be followed by a 4-month observation period.